证券代码：002864 证券简称：盘龙药业 公告编号：2026-011 陕西盘龙药业集团股份有限公司 关于公司申请银行授信并接受关联方提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关联交易概述 陕西盘龙药业集团股份有限公司（以下简称"公司"）因发展需要拟加强与 金融机构的合作，拟向中国银行股份有限公司西安高新技术开发区支行申请流动 资金贷款一亿元（人民币）。公司实际控制人谢晓林及其配偶为本次融资提供连 带责任保证，本次担保不向公司收取任何担保费用，亦无需公司提供反担保。 根据《深圳证券交易所股票上市规则》（以下简称"《股票上市规则》"）的 相关规定，谢晓林及其配偶为公司关联自然人。因此，其为公司申请授信额度提 供担保构成关联交易事项。 本次向银行申请授信及接受关联方担保事项已经公司第五届董事会第四次 会议以 7 票赞成、0 票反对、0 票弃权审议通过，关联董事谢晓林、谢晓锋就该 事项回避表决。该事项已经独立董事专门会议审议通过，并经公司全体独立董事 同意。根据《股票上市规则》本次关联交易无需提交公司股东会审议。 本次关联交易事项不构成《上 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2026-010 陕西盘龙药业集团股份有限公司 第五届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 陕西盘龙药业集团股份有限公司（以下简称"公司"）第五届董事会第四次 会议通知于 2026 年 3 月 13 日以邮件方式向各位董事、独立董事发出。本次会议 于 2026 年 3 月 17 日上午 9:00，在西安市灞桥区现代纺织产业园灞柳二路 2801 号陕西盘龙医药股份有限公司二楼会议室采用现场与通讯相结合方式召开。会议 应出席董事 9 名，实际出席董事 9 名（其中牛晓峰先生、王满仓先生以通讯方式 出席本次会议）。会议由公司董事长谢晓林先生召集并主持。公司全体高级管理 人员列席了本次会议。 会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律、行政 法规、部门规章、规范性文件及《陕西盘龙药业集团股份有限公司章程》的有关 规定。 二、董事会会议审议情况 经与会董事认真审议，形成以下决议： 审议通过了《关于公司申请银行授信并接受关联方提供担保的议案》 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2026-009 陕西盘龙药业集团股份有限公司 关于董事减持股份实施完成的公告 董事朱文锋先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于 2026 年 2 月 4 日 披露了《关于董事减持股份预披露公告》（公告编号：2026-004）。公司董事朱 文锋先生计划自减持公告披露之日起 15 个交易日后的 3 个月内（即 2026 年 3 月 5 日至 2026 年 6 月 4 日期间），以集中竞价方式减持公司股份数量不超过 22,500 股（占剔除公司已回购股份的总股本比例为 0.0212%）。 公司近日收到公司董事朱文锋先生出具的《公司股份减持计划实施完成告知 函》，现将具体情况公告如下： 一、股东的减持情况 注 2：占总股本比例以剔除回购专用账户股份数量后公司总股本计算（下同）。 注 3：减持价格区间为 33.33 元/股 至 33.6 元/股。 | 股东名 | | 本次减持前持有股份 | | 本次 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2026-007 陕西盘龙药业集团股份有限公司 陕西盘龙药业集团股份有限公司（以下简称"公司"）董事会于近日收到公 司证券事务代表赵晓妮女士提交的书面辞职报告，赵晓妮女士因个人原因辞去公 司证券事务代表一职。辞职后，赵晓妮女士将不再担任公司及控股子公司的任何 职务，其辞职报告自送达董事会之日起生效。赵晓妮女士的辞职不会影响公司相 关工作的正常开展。 截至本公告披露日，赵晓妮女士未持有公司股份，不存在应当履行而未履行 的承诺事项。公司及公司董事会对其在担任证券事务代表期间的履职付出表示衷 心感谢。公司将根据《深圳证券交易所股票上市规则》、《深圳证券交易所上市公 司自律监管指引第 1 号——主板上市公司规范运作》等相关规定，尽快聘任符合 任职资格的相关人员担任证券事务代表，协助公司董事会秘书开展工作。 特此公告。 陕西盘龙药业集团股份有限公司董事会 2026 年 3 月 3 日 1 关于证券事务代表辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

陕西盘龙药业集团股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002864 证券简称：盘龙药业 公告编号：2026-008 近日，陕西盘龙药业集团股份有限公司（以下简称"公司"）收到国家药品 监督管理局颁发的关于硫酸氨基葡萄糖胶囊（以下简称"该药品"）的《药品注 册证书》，现将相关情况公告如下： 一、药品的基本情况 药品名称：硫酸氨基葡萄糖胶囊 剂型：胶囊剂 规格：0.25g（按硫酸氨基葡萄糖计）或 0.314g（按硫酸氨基葡萄糖氯化钠 计） 注册分类：化学药品 4 类 证书编号：2026S00530 药品批准文号：国药准字 H20263442 上市许可持有人：陕西盘龙药业集团股份有限公司 生产企业：广州华圣制药有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。同意本品按甲类非处 方药管理。 二、药品的相关信息 硫酸氨基葡萄糖胶囊适用于原发性及继发性骨关节炎。硫酸氨基葡萄糖胶囊 原研药于 1982 年在意大利获批上市，持证商为 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [1] Core Insights - The upcoming adjustment of the National Essential Medicines List (NEML) is expected to benefit traditional Chinese medicine (TCM) stocks, with a focus on companies like Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17][22] - The report ranks sub-sectors in the following order of preference: innovative drugs > research services > CXO > TCM > medical devices > pharmacies [2][11] - Historical data indicates that products included in the NEML tend to experience significant sales growth, as seen with Zhaoli Pharmaceutical's Wuling Capsule, which saw sales growth rates increase from -12.82% in 2017 to 32.52% in 2021 after being included in the NEML [19][22] Summary by Sections Investment Highlights - The report suggests focusing on TCM stocks due to the imminent NEML adjustments, recommending Zhaoli Pharmaceutical, Fangsheng Pharmaceutical, and Panlong Pharmaceutical [2][17] - The report emphasizes the importance of the NEML adjustments, which have not occurred in eight years, and the potential for TCM products to gain market share [22] R&D Progress and Company Dynamics - Recent approvals and submissions include Sanofi's Dupilumab for new indications and GSK's hepatitis B therapy application in Japan [5] - The report highlights various companies across different therapeutic areas, including innovative drugs, ADCs, and small nucleic acids, suggesting a diversified investment approach [13][22] Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 3.0%, with notable performances from specific stocks such as Aidi Te (+36.9%) and Wanze Shares (+27.5%) [10] - The report notes that the medical sector has seen varied performance, with biopharmaceuticals and medical devices showing positive trends, while chemical pharmaceuticals and medical services have faced declines [10]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Group 1 - The company has received approval from the National Medical Products Administration for clinical trials of Ketoprofen Gel Patch, which is intended for pain relief [1] - The product is classified as a Class 3 chemical drug and is indicated for conditions such as osteoarthritis, shoulder periarthritis, tendonitis, and muscle pain [1] - The Ketoprofen Gel Patch contains 30mg of Ketoprofen per 10g of gel and is administered topically, with a recommended dosage of one patch twice daily [1] Group 2 - Sales of Ketoprofen Gel Patch in China's major markets are projected to be approximately 49.58 million yuan in 2024 and about 76.44 million yuan in the first half of 2025 [2] - The approval for clinical trials is expected to enhance the company's product pipeline in the orthopedic chronic disease sector, potentially improving its strategic goals and core competitiveness [3] - The company acknowledges the long development cycle and high investment associated with drug research, which may introduce uncertainties regarding the approval and market performance of the product [3]

Core Viewpoint - The announcement by Panlong Pharmaceutical regarding the approval of clinical trials for Ketoprofen gel patches indicates a significant step in the development of pain relief treatments, particularly for osteoarthritis [1] Company Summary - Panlong Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of Ketoprofen gel patches [1] - The product is a chemical drug in the 3rd category, with specifications of 14cm×10cm containing 30mg of Ketoprofen [1] - Currently, the only other company with a similar product approved for market in China is Hunan Jiudian Pharmaceutical [1] Industry Summary - The approval of Ketoprofen gel patches highlights the ongoing development and competition in the pain relief market, particularly for localized treatments for conditions like osteoarthritis [1] - The market for such products may see increased activity as more companies seek to develop and approve similar pain management solutions [1]

Core Viewpoint - The company, Panlong Pharmaceutical (002864.SZ), has received approval from the National Medical Products Administration for clinical trials of its ketoprofen gel patch, indicating a significant step in its product development pipeline [1]. Group 1: Product Details - The ketoprofen gel patch is designed for local application, with each patch measuring 14cm x 10cm and containing 10g of gel, which includes 30mg of ketoprofen [1]. - The patch is indicated for pain relief and anti-inflammatory treatment for conditions such as osteoarthritis, periarthritis of the shoulder, tendinitis, de Quervain's tenosynovitis, lateral epicondylitis (tennis elbow), muscle pain, and swelling and pain due to trauma [1]. - The administration method involves applying one patch twice a day [1]. Group 2: Regulatory Classification - The product is classified as a Class 3 chemical drug according to registration standards [1].